The Promising Field of Targeted Protein Degraders (TPDs)

Back Bay Life Science Report

with Back Bay Life Science Advisors’ Dr. Peter Bak and Dr. Mavra Nasir

Dr. Mavra Nasir recently published a thought piece in Biopharma Dealmakers outlining the current state of play in the promising field of protein degradation. In this episode, Dr. Nasir sits down with Peter Bak to discuss the recent surge of venture funding and partnerships surrounding TPDs.

Read Dr. Nasir's article "From drug target inhibition to degradation: a TACtical strategy" here.

Topics in this podcast include:

• An intro into targeted protein degradation (TPDs) and proteolysis-targeting chimeras (PROTACs)
• Industry advantages of TPDs vs. traditional antibodies
• Biopharma and VC's growing interest in molecular glues
• Commercial hurdles ahead in this space
• How TPD companies can differentiate, from a pipeline and breadth of opportunities to select an indication, communicate to investors and drive value

If you have a question about life sciences development, submit it here. We may feature it on an upcoming episode.

Thanks for joining us!

*

Mavra Nasir, PhD is a senior consultant at Back Bay Life Science Advisors where she supports strategic engagements across a range of therapeutic areas including rare diseases, hematology/oncology and metabolic diseases for biopharma and MedTech. Dr. Nasir joined Back Bay after receiving her PhD in Quantitative Biomedical Sciences from Dartmouth College.